Literature DB >> 1277725

Kinetics and dose calculations of amikacin in the newborn.

H Sardemann, H Colding, J Hendel, J P Kampmann, E F Hvidberg, R Vejlsgaard.   

Abstract

The pharmacokinetics of a new aminoglycoside, amikacin, was evaluated in 37 infants between 1 and 34 days old. Fifteen were below 2,500 gm in weight. Initial studies, including intravenous infusion in some of the infants, indicated that the disposition of amikacin was best described by a 2 compartment model. The absorption was evaluated in 8 of the infants after intramuscular injection of 7.5 mg amikacin per kilogram of body weight. The absorption rate, estimated by the tmax, was significantly faster than reported in adults. The total body clearance and apparent volume of distribution were studied in 22 infants after the same dose of amikacin intramuscularly. The body clearance expressed in relation to body surface or body weight was significantly less than in adults and correlated with the postnatal age. No correlation could be demonstrated between clearance and gestational age or birth weight. The volume of distribution per kilogram was significantly greater than in adults. On the basis of the derived kinetic parameters, a dose schedule is presented. In 5 children there was a reasonable agreement between the measured and predicted serum levels.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277725     DOI: 10.1002/cpt197620159

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Comparison of Amikacin Pharmacokinetics in Neonates With and Without Congenital Heart Disease.

Authors:  Amy L Nguyen; Peter N Johnson; Stephen B Neely; Kaitlin M Hughes; Kris C Sekar; Robert C Welliver; Jamie L Miller
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

2.  Effects of gestational age, birth weight, and hypoxemia on pharmacokinetics of amikacin in serum of infants.

Authors:  M G Myers; R J Roberts; N J Mirhij
Journal:  Antimicrob Agents Chemother       Date:  1977-06       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

4.  Comparison of Amikacin Pharmacokinetics in Neonates Following Implementation of a New Dosage Protocol.

Authors:  Kaitlin M Hughes; Peter N Johnson; Michael P Anderson; Kris C Sekar; Robert C Welliver; Jamie L Miller
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

Review 5.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

6.  Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.

Authors:  J M Tréluyer; Y Merlé; S Tonnelier; E Rey; G Pons
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

7.  Amikacin pharmacokinetics in pediatric patients with malignancy.

Authors:  T G Cleary; L K Pickering; W G Kramer; S Culbert; L S Frankel; S Kohl
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

Review 8.  Clinical pharmacokinetics of aminoglycosides in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Eur J Clin Pharmacol       Date:  2008-12-23       Impact factor: 2.953

9.  Effects of hypoxemia upon aminoglycoside serum pharmacokinetics in animals.

Authors:  N J Mirhij; R J Roberts; M G Myers
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

Review 10.  Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.

Authors:  Charlotte I S Barker; Eva Germovsek; Rollo L Hoare; Jodi M Lestner; Joanna Lewis; Joseph F Standing
Journal:  Adv Drug Deliv Rev       Date:  2014-01-17       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.